Literature DB >> 34907718

Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA.

Karen Ingrid Tasca1, Vania V M Fagundes Vidal2, Vanessa Martinez Manfio3, Alexandre Naime Barbosa2,3, Lenice do Rosario de Souza2,3.   

Abstract

BACKGROUND: Despite the many benefits that follow antiretroviral therapy (ART) initiation, its chronic use contributes to the early aging of people living with HIV/AIDS (PLWHA). The aim of this cross-sectional study was to trace the prevalence of and investigate possible renal, bone and metabolic changes, as well as cardiovascular risk in 94 asymptomatic PLWHA, relating them to the duration of ART use.
METHODS: Four groups were evaluated according to ART use: G1 (n = 21), ART-naïve individuals; G2 (n = 17), <2 years; G3 (n = 40), 2-10 years; and G4 (n = 16) on ART for more than 10 years.
RESULTS: Our results showed a high prevalence of dyslipidemic individuals (64%), especially in those under ART. Lower creatine phosphokinase levels were observed in G1 as compared to the others (p < 0.05). Regarding the Framingham score, 12.1% of PLWHA showed moderate and high risk, and the highest proportion (38.5%) occurred in G4 (p = 0.003). A decrease in glomerular filtration rates occurred in 20% of patients, which was also more significant in G3 and G4 (p = 0.007). High prevalences of osteopenia and osteoporosis (53.2%) were found, especially in G1 and G4; however, G1 showed the lowest means for alkaline phosphatases (AP, p = 0.04 and BAP, p = 0.005) and osteocalcin (p = 0.005), in addition to higher vitamin-D concentrations (p = 0.04).
CONCLUSIONS: Our study showed the possible contributory role of ART in these changes, which leads us to reflect on the need for specific conducts and patient care, pointing out the importance of individualized care in an attempt to increase life expectancy.

Entities:  

Keywords:  Antiretroviral; Dyslipidemia; HIV/Aids; Non-AIDS comorbidities

Mesh:

Year:  2021        PMID: 34907718     DOI: 10.32725/jab.2021.002

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  56 in total

Review 1.  Cardiovascular disease in patients with HIV.

Authors:  Flavia Ballocca; Fabrizio D'Ascenzo; Sebastiano Gili; Walter Grosso Marra; Fiorenzo Gaita
Journal:  Trends Cardiovasc Med       Date:  2017-06-12       Impact factor: 6.677

2.  Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Authors:  B M Bergersen; L Sandvik; J N Bruun; S Tonstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

3.  Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  R Bijker; A Jiamsakul; E Uy; N Kumarasamy; R Ditango; R Chaiwarith; W W Wong; A Avihingsanon; L P Sun; E Yunihastuti; S Pujari; C D Do; T P Merati; P Kantipong; K V Nguyen; A Kamarulzaman; F Zhang; M P Lee; J Y Choi; J Tanuma; O T Ng; Blh Sim; J Ross; S Kiertiburanakul
Journal:  HIV Med       Date:  2019-01-08       Impact factor: 3.180

4.  High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.

Authors:  Anna Bonjoch; Marta Figueras; Carla Estany; Núria Perez-Alvarez; Joaquim Rosales; Luís del Rio; Silvana di Gregorio; Jordi Puig; Guadalupe Gómez; Bonaventura Clotet; Eugènia Negredo
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

5.  Increased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern Africa.

Authors:  Michael Bestawros; Takondwa Chidumayo; Meridith Blevins; Ashley Canipe; Jay Bala; Paul Kelly; Suzanne Filteau; Bryan E Shepherd; Douglas C Heimburger; John R Koethe
Journal:  J AIDS Clin Res       Date:  2015-03

6.  Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.

Authors:  Mark J Bolland; Andrew B Grey; Anne M Horne; Simon E Briggs; Mark G Thomas; Rod B Ellis-Pegler; Andrew F Woodhouse; Greg D Gamble; Ian R Reid
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

Review 7.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.

Authors:  Todd T Brown; Roula B Qaqish
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

Review 8.  Skeletal health in adults with HIV infection.

Authors:  Mark J Bolland; Andrew Grey; Ian R Reid
Journal:  Lancet Diabetes Endocrinol       Date:  2014-02-26       Impact factor: 32.069

9.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.

Authors:  Todd T Brown; Grace A McComsey
Journal:  Antivir Ther       Date:  2010       Impact factor: 1.679

10.  Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.

Authors:  Eric Bonnet; Jean-Bernard Ruidavets; Anne Genoux; Laurence Mabile; Florian Busato; Martine Obadia; François Prévoteau; Bruno Marchou; Patrice Massip; Fabrice Marion-Latard; Cyrille Delpierre; Jacques Bernard; Bertrand Perret
Journal:  BMC Infect Dis       Date:  2013-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.